Jupiter Topco LLC Invests $822,000 in ADMA Biologics Inc $ADMA

Jupiter Topco LLC bought a new stake in ADMA Biologics Inc (NASDAQ:ADMA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 98,261 shares of the biotechnology company’s stock, valued at approximately $822,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Royal Bank of Canada boosted its position in shares of ADMA Biologics by 112.7% during the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in ADMA Biologics during the first quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ADMA Biologics by 59.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after purchasing an additional 305,064 shares in the last quarter. Norges Bank purchased a new stake in ADMA Biologics during the 2nd quarter worth approximately $549,000. Finally, EverSource Wealth Advisors LLC boosted its position in ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 2,180 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $9.62 on Monday. The stock has a market cap of $2.15 billion, a P/E ratio of 13.74 and a beta of 0.78. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46. The company’s 50 day moving average is $9.15 and its two-hundred day moving average is $10.27.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same period last year, the firm posted $0.14 EPS. The company’s revenue was up 2.0% on a year-over-year basis. Research analysts expect that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ADMA has been the topic of a number of analyst reports. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Mizuho decreased their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Finally, Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics presently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.